Cargando…

Monographs for medicines on WHO’s Model List of Essential Medicines

OBJECTIVE: To raise awareness about the importance of public pharmaceutical standards, identify if and, if so, where current pharmacopeias are falling short in the development of new and complete monographs and foster collaboration among the various pharmacopeias, to prioritize, develop and make ava...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Lukas, Adler, Melissa, Jain, Tanvi, Bempong, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Health Organization 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996216/
https://www.ncbi.nlm.nih.gov/pubmed/29904220
http://dx.doi.org/10.2471/BLT.17.205807
_version_ 1783330796717735936
author Roth, Lukas
Adler, Melissa
Jain, Tanvi
Bempong, Daniel
author_facet Roth, Lukas
Adler, Melissa
Jain, Tanvi
Bempong, Daniel
author_sort Roth, Lukas
collection PubMed
description OBJECTIVE: To raise awareness about the importance of public pharmaceutical standards, identify if and, if so, where current pharmacopeias are falling short in the development of new and complete monographs and foster collaboration among the various pharmacopeias, to prioritize, develop and make available standards for those key medicines for which no complete monographs exist. METHODS: In August 2017, we mined eight pharmacopeias to identify which of the 669 medicines in the 20th edition of the World Health Organization’s Model List of Essential Medicines were covered by complete or incomplete monographs. The pharmacopeias we included were the Brazilian Pharmacopoeia, the British Pharmacopoeia, the Indian Pharmacopeia Commission, the International Pharmacopoeia, the Japanese Pharmacopoeia, the Mexican Pharmacopoeia, the Pharmacopeia of the People’s Republic of China and the United States Pharmacopeia. FINDINGS: For 99 (15%) of the medicines on the Model List, no monographs were available in any of the eight pharmacopeias investigated. Only 3% (1/30) of the cardiovascular medicines listed, but 28% (9/32) of the antiretroviral medicines and 23% (6/26) of the antimalarial medicines lacked monographs. CONCLUSION: There appear to be no public standards for many so-called essential medicines. To address this shortfall, a greater collaboration in the global health community is needed.
format Online
Article
Text
id pubmed-5996216
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher World Health Organization
record_format MEDLINE/PubMed
spelling pubmed-59962162018-06-14 Monographs for medicines on WHO’s Model List of Essential Medicines Roth, Lukas Adler, Melissa Jain, Tanvi Bempong, Daniel Bull World Health Organ Research OBJECTIVE: To raise awareness about the importance of public pharmaceutical standards, identify if and, if so, where current pharmacopeias are falling short in the development of new and complete monographs and foster collaboration among the various pharmacopeias, to prioritize, develop and make available standards for those key medicines for which no complete monographs exist. METHODS: In August 2017, we mined eight pharmacopeias to identify which of the 669 medicines in the 20th edition of the World Health Organization’s Model List of Essential Medicines were covered by complete or incomplete monographs. The pharmacopeias we included were the Brazilian Pharmacopoeia, the British Pharmacopoeia, the Indian Pharmacopeia Commission, the International Pharmacopoeia, the Japanese Pharmacopoeia, the Mexican Pharmacopoeia, the Pharmacopeia of the People’s Republic of China and the United States Pharmacopeia. FINDINGS: For 99 (15%) of the medicines on the Model List, no monographs were available in any of the eight pharmacopeias investigated. Only 3% (1/30) of the cardiovascular medicines listed, but 28% (9/32) of the antiretroviral medicines and 23% (6/26) of the antimalarial medicines lacked monographs. CONCLUSION: There appear to be no public standards for many so-called essential medicines. To address this shortfall, a greater collaboration in the global health community is needed. World Health Organization 2018-06-01 2018-03-28 /pmc/articles/PMC5996216/ /pubmed/29904220 http://dx.doi.org/10.2471/BLT.17.205807 Text en (c) 2018 The authors; licensee World Health Organization. This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.
spellingShingle Research
Roth, Lukas
Adler, Melissa
Jain, Tanvi
Bempong, Daniel
Monographs for medicines on WHO’s Model List of Essential Medicines
title Monographs for medicines on WHO’s Model List of Essential Medicines
title_full Monographs for medicines on WHO’s Model List of Essential Medicines
title_fullStr Monographs for medicines on WHO’s Model List of Essential Medicines
title_full_unstemmed Monographs for medicines on WHO’s Model List of Essential Medicines
title_short Monographs for medicines on WHO’s Model List of Essential Medicines
title_sort monographs for medicines on who’s model list of essential medicines
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996216/
https://www.ncbi.nlm.nih.gov/pubmed/29904220
http://dx.doi.org/10.2471/BLT.17.205807
work_keys_str_mv AT rothlukas monographsformedicinesonwhosmodellistofessentialmedicines
AT adlermelissa monographsformedicinesonwhosmodellistofessentialmedicines
AT jaintanvi monographsformedicinesonwhosmodellistofessentialmedicines
AT bempongdaniel monographsformedicinesonwhosmodellistofessentialmedicines